KCTD1 Activators
KCTD1 Activators comprise a spectrum of chemical entities that enhance the functionality of KCTD1 through indirect engagement with various cellular mechanisms. Forskolin, by increasing intracellular cAMP, activates protein kinase A (PKA), which may phosphorylate targets associated with KCTD1, thereby potentially augmenting its regulatory roles in cellular processes such as ion channel modulation. Concurrently, Sphingosine-1-phosphate, through its engagement with MAPK and PI3K pathways, could influence post-translational modifications of proteins within KCTD1's sphere, potentially enhancing KCTD1's activity. Similarly, Thapsigargin and A23187, by raising intracellular calcium, may activate calcium-dependent signaling cascades that KCTD1 is implicated in, potentially leading to an upsurge in KCTD1's functional activity.
The activation spectrum further broadens with the inclusion of PMA, LY294002, Wortmannin, U0126, SB203580, and Staurosporine, each contributing uniquely to the elevation of KCTD1's functional state. PMA, as a PKC activator, could indirectly affect KCTD1 if it intersects with PKC-regulated pathways. LY294002 and Wortmannin, as PI3K inhibitors, might shift the intracellular signaling balance to enhance pathways involving KCTD1. Inhibitors like U0126 and SB203580, which target MEK1/2 and p38 MAPK respectively, could relieve inhibitory pressures on KCTD1-related pathways, thus facilitating its activation. Epigallocatechin gallate, by its broad-spectrum kinase inhibition, might create a signaling milieu that favors KCTD1 activation. Lastly, Staurosporine and Genistein, through their broad kinase inhibitory effects, could selectively activate KCTD1 by reducing negative regulatory influences, thereby enhancing KCTD1's function within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, leading to an increase in cAMP levels. Elevated cAMP activates PKA, which can regulate ion channels and other proteins that KCTD1 may interact with, thereby potentially enhancing KCTD1's role in modulating these channels and neuronal excitability. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate acts on its receptors to activate downstream MAPK and PI3K pathways, which are involved in the regulation of a variety of cellular functions. KCTD1 could be influenced by these pathways through post-translational modifications that alter its function or localization. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to a rise in cytosolic calcium levels. Increased calcium can activate various calcium-dependent proteins, potentially influencing KCTD1 function as it could be involved in pathways responsive to calcium signaling. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate a wide range of target proteins. Through PKC activation, KCTD1 may be indirectly affected if it interacts with PKC substrates or is regulated by PKC-mediated signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that may increase the activation of compensatory pathways or proteins that KCTD1 is involved with, enhancing KCTD1's functional role in the cell by altering the balance of signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, which could similarly shift cellular signaling pathways towards those that KCTD1 influences, thus indirectly enhancing KCTD1's activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAPK, potentially altering the signaling landscape in a way that benefits pathways or processes where KCTD1 is active, indirectly enhancing its function. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits several protein kinases and has been shown to modulate signal transduction pathways. This broad inhibition could tip the balance of cellular signaling in favor of pathways involving KCTD1, leading to its enhanced functional activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a calcium ionophore, which increases intracellular calcium levels, activating calcium-dependent signaling pathways. This can indirectly enhance the activity of KCTD1 if it is part of or modulates such calcium-dependent pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor that, while broadly targeting kinases, could lead to the selective activation of pathways where KCTD1 is active by inhibiting negative regulatory kinases that affect KCTD1 function. | ||||||